NASDAQ:EDIT - Nasdaq - US28106W1036 - Common Stock - Currency: USD
NASDAQ:EDIT (2/21/2025, 1:06:07 PM)
1.945
-0.11 (-5.58%)
The current stock price of EDIT is 1.945 USD. In the past month the price increased by 53.73%. In the past year, price decreased by -73.62%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.02 | 358.05B | ||
AMGN | AMGEN INC | 15.1 | 160.69B | ||
GILD | GILEAD SCIENCES INC | 23.96 | 137.62B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.41 | 124.37B | ||
REGN | REGENERON PHARMACEUTICALS | 15.32 | 76.45B | ||
ARGX | ARGENX SE - ADR | N/A | 39.37B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.09B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.09B | ||
NTRA | NATERA INC | N/A | 21.14B | ||
BIIB | BIOGEN INC | 8.51 | 20.43B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.71B |
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 265 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The company is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141 US
CEO: James C. Mullen
Employees: 265
Company Website: https://www.editasmedicine.com/
Investor Relations: https://ir.editasmedicine.com
Phone: 16174019000
The current stock price of EDIT is 1.945 USD. The price decreased by -5.58% in the last trading session.
The exchange symbol of EDITAS MEDICINE INC is EDIT and it is listed on the Nasdaq exchange.
EDIT stock is listed on the Nasdaq exchange.
22 analysts have analysed EDIT and the average price target is 4.53 USD. This implies a price increase of 133.07% is expected in the next year compared to the current price of 1.945. Check the EDITAS MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EDITAS MEDICINE INC (EDIT) has a market capitalization of 160.56M USD. This makes EDIT a Micro Cap stock.
EDITAS MEDICINE INC (EDIT) currently has 265 employees.
The Revenue of EDITAS MEDICINE INC (EDIT) is expected to grow by 14.24% in the next year. Check the estimates tab for more information on the EDIT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EDIT does not pay a dividend.
EDITAS MEDICINE INC (EDIT) will report earnings on 2025-02-26, after the market close.
EDITAS MEDICINE INC (EDIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.56).
The outstanding short interest for EDITAS MEDICINE INC (EDIT) is 20.77% of its float. Check the ownership tab for more information on the EDIT short interest.
ChartMill assigns a technical rating of 5 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT is a bad performer in the overall market: 95.01% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to EDIT. EDIT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -2.56. The EPS increased by 5.19% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -64.28% | ||
ROE | -119.89% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 70% to EDIT. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of -33.3% and a revenue growth 14.24% for EDIT